The all-stock deal, paired with a $200 million raise, hands Processa a once-daily, brain-penetrating BTK inhibitor targeting food allergy, chronic urticaria and multiple sclerosis.
Eleven of twenty Phase 3 starts in 2026 are cancer trials. The dolutegravir patents expire 2028–2030, and that is the deadline the whole plan is set against.
The constraint is not the molecule or the market. It is the number of people qualified to run peptide synthesis at commercial scale under pharmaceutical quality systems.
42% of patients on the drug reached zero heavy-drinking days. In a condition where three medications exist and few people take them, that number matters.
Retrieval, not training. The distinction determines who owns what, and it is why this deal was possible when others have ended in court.
Three drugs was never a biological requirement. It was insurance against resistance — and modern drugs made the insurance less necessary.
$5.5 billion, 69,000 claims, and no admission. After two failed bankruptcy manoeuvres, the company is settling on ordinary terms.
Three neurotransmitters at once, no stimulant. The first genuinely new mechanism in ADHD in years, and the first that adds serotonin.
81% sensitivity for cancer, 13.7% for the polyps colonoscopy removes before they become cancer. The second number is what the test cannot do.
The tumour shortens one messenger RNA, which destroys the flag T cells look for. Forcing the RNA back to full length puts the flag back.
Some people carry the plaques and never decline. The difference may be whether their microglia crossed one threshold — and stayed on the right side of it.
People with almost no body fat develop the metabolic disease associated with obesity. That paradox is what fat tissue failing actually looks like.